AstraZeneca To Acquire Alexion Pharmaceuticals for $39 Billion The deal will be AstraZeneca's largest acquisition, helping it to diversify from its fast-growing cancer business into rare diseases and immunology. 4 MIN READ 12.14.2020
5 Things to Know About Moderna’s Proposed $500 Million IPO The proposed deal for this biotechnology unicorn would be the largest US IPO in the industry (Image: Moderna) 6 MIN READ 11.12.2018
Dicerna Signs Potential Multi Billion Dollar Licensing and Research Deal with Lilly $100 million upfront + $100 million in equity + up to $350 million in milestone payments per target for at least 10 targets (Image: Dicerna Pharmaceuticals) 4 MIN READ 10.29.2018
Alexion to Acquire Wilson Therapeutics for $855 Million Wilson's lead product candidate is in Phase 3 trials to treat Wilson disease, a rare genetic liver disorder. 3 MIN READ 04.11.2018
Alexion Announces Positive Phase 3 Results for Rare Blood Disorder Treatment Study comparing investigational long-acting treatment vs Soliris, Alexion's approved drug. 2 MIN READ 03.15.2018
How Alexion Strengthens in Risk-Reward Equation Alexion Pharmaceuticals researches and manufactures treatments of severe and rare health disorders. 2 MIN READ 12.14.2017
